AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02962310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor 40 mg Tablets of AstraZeneca LP, USA
Description: oral, crossover
Study NCT01361750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric tube
Description: the stomach will be cut into a narrowed tube-shape conduit
Study NCT05366595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral zinc sulfate
Description: Oral zinc sulfate at dose 10 to 20 mg daily for 10 days
Study NCT03721224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Kiddie Schedule for Affective Disorders and Schizophrenia
Description: Both of the clinical and control group will be evaluated via Psychiatric semi-structured interview
Study NCT01057355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS and/or ERCP with ethanol injections of pancreatic cyst
Description: Lavage of cyst with 80% ethanol
Study NCT04007965 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Posterior Capsulorhexis
Description: Pneumatic Posterior Capsulorhexis using air dose 0.1 ml and Healon dose 0.5 -1.0 ml.
Study NCT04007965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic Posterior Capsulorhexis
Description: Pneumatic Posterior Capsulorhexis using air dose 0.1 ml and Healon dose 0.5 -1.0 ml.
Study NCT02725658 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DOSI
Description: Breast tissue properties scanning
Study NCT03566095 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching and Voices for Food Kit
Description: Community Coaching and Voices for Food Kit
Study NCT03566095 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Voices for Food Kit
Description: Voices for Food Kit
Study NCT01979874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pro-Omega
Description: Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day x 3 months
Study NCT01979874 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ProOmega Placebo
Description: Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
Study NCT01961414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits
Study NCT01699048 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hybrid (MIDCAB+PCI)
Description: Hybrid approach (Minimally invasive of-pump revascularization of the left anterior descending artery (LAD) via left internal mammary artery (LIMA) bypass with consecutive percutaneous coronary intervention (PCI) in the rest arteries with drug eluting stents (DES). The revascularization will be performed in two stages within a 3-days interval
Study NCT01699048 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PCI
Description: Multi-vessel PCI with DES
Study NCT01699048 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CABG
Description: Coronary artery bypass graft (CABG) treatment
Study NCT02346708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TMS
Description: real treatment
Study NCT02346708 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: placebo treatment
Study NCT04758013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural injection through thoracic epidural catheter
Description: The investigators inject drugs through a catheter inserted into the thoracic epidural space to control pain after surgery in patients undergoing gastric surgery by laparoscopy.
Study NCT04758013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without epidural injection
Description: The investigators don't epidural injection to find out the effect of only inter-abdominal pressure on intracranial pressure.
Study NCT03928054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping and therapeutic alliance
Description: bandage used in the treatment of orthopedic diseases and the technique of therapeutic approach in the known patient with therapeutic alliance
Study NCT00614874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: 2mg, 4mg, 8mg
Study NCT01687114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cranberry juice
Description: 27% cranberry juice
Study NCT04488913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RACE-IT Pathway
Description: This care pathway includes the evaluation of suspected acute coronary syndrome with high-sensitivity troponin I testing and further prognostication as needed with a modified HEART score
Study NCT04488913 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care protocol that uses the 99th percentile troponin values for evaluation of suspected acute coronary syndrome and further prognostication using the HEART score
Study NCT03286387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional brain imaging without any contrast agent
Description: During the fMRI protocol, the subject will perform the retrieval tasks while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (TE) = 30 ms, Repetition Time (TR) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min).
Study NCT02593877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VHA algorithm
Description: Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)
Study NCT00233480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: atorvastatin 10mg PO QD
Study NCT00233480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched placebo Qd x 3 months
Study NCT04086277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Intrapartum Support
Description: Received the usual obstetric care plus continuous intrapartum support that was provided by a Bachelor of Nursing and Obstetrics who received prior training by a professional doula.
Study NCT00278447 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Disease Management for substance abuse
Description: Referral to primary medical care \& longitudinal, multidisciplinary care for persons with substance dependence.
Study NCT00278447 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Referral to primary medical care for persons with substance dependence.
Study NCT03563326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting EpCAM
Description: Biological: CAR-T cells targeting EpCAM
Study NCT03563326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy: determined by medical Oncologist
Study NCT03563326 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy: determined by medical Oncologist
Study NCT01736943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.
Study NCT01736943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.
Study NCT00387426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study NCT03518190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared spectroscopy (ODP)
Description: Infrared spectroscopy device will be used to detect non-visible pressure injuries
Study NCT00053885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Description: oral
Study NCT03472131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral Posterolateral Approach and Debridement
Study NCT03472131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titanium cage insertion supplemented by screw fixation
Study NCT02457195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: Application granisetron transdermal patch preoperatively
Study NCT01703494 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual (donor) to a sick patient (with relapsing C. difficile infection) to restore missing components of normal intestinal flora. After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal microbiota transplantation (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
Study NCT01703494 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham Fecal Microbiota Transplantation
Description: After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive a sham fecal microbiota transplantation (FMT) with a 300 mL sham fecal suspension delivered via colonoscopy. This sham solution will be a reinfusion of the subject's own stool.
Study NCT03760224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WhatsApp group
Description: WhatsApp group will allow real-time group discussion for 8 weeks
Study NCT03760224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS group
Description: SMS group for 8 weeks
Study NCT02871674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good Night Project
Description: The behavioural interventions have been designed on the basis of three sources. Firstly, a systematic review conducted by the research team that examined the best evidence in the field in different countries. Secondly, a Delphi study, which aimed to identify behavioural interventions that can be used to manage sleep difficulties in Saudi Arabia in accordance with professionals' views and primary caregivers' needs, and which was also conducted by the research team. Thirdly, evidence-based practice resources that help in understanding and managing sleep difficulties will be translated into Arabic.
Study NCT01816321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: Corifollitropin alfa 150μg on day 2 of the menstrual cycle (stimulation day 1)
Study NCT01816321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering
Study NCT01816321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix 0.25mg/daily from day 7 of the cycle(stimulation day 6) until day of ovulation triggering
Study NCT01816321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: Ganirelix 0.25mg/daily from day 7 of the cycle(stimulation day 6) until day of ovulation triggering
Study NCT01816321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hp HMG
Description: hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering
Study NCT00920153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD regimen
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00547014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator: Cohort 1 Placebo
Description: Drug: placebo for cohort 1 as single dose
Study NCT00547014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 52364 3 mg
Description: 3 mg capsule single dose administered orally as a single dose
Study NCT00547014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo
Description: Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
Study NCT00547014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 52364 10 mg
Description: Drug: 52364 30 mg capsule as a single dose
Study NCT00547014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 52364 30 mg
Description: Drug: 52364 30 mg capsule administered as a single dose
Study NCT00547014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 52364 100 mg
Description: Drug 52364 100 mg capsule administered as a single dose
Study NCT00547014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 52364 1 mg
Description: 1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoguazone
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine
Description: Given IV
Study NCT00920153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT00570284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
Study NCT05102877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Motor stimulation was administered at an intensity sufficient to produce muscle contractions. Sensory stimulation was defined as the threshold when the patient feels a tingling sensation on their skin.
Study NCT00920153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Patients undergo allogeneic stem cell transplantation
Study NCT00920153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Patients undergo autologous stem cell transplantation
Study NCT01551966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless esophageal capsule endoscopy ( PillCam Eso2)
Description: This is a simple blind (blind for the lecture of the capsule endoscopy record) study to evaluate the diagnostic value of the capsule endoscopy for the detection and the control of esophageal varices, the feasibility, tolerance and safety of the capsule endoscopy compared to the conventional EGD under general sedation in children presenting with portal hypertension.~During one week, the patients will undergo two exams (capsule endoscopy and EGD under general sedation). The exams will be done by two different physicians.~For to asses the tolerance, after they completed both exams, the patients will be asked to answer a comfort score questionnaire.~In order to asses the safety of the capsule endoscopy, the patients will be followed for adverse events during 3 weeks after the completion of the capsule endoscopy.
Study NCT02427841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02427841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT02427841 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo IG-IMRT
Study NCT02427841 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IG-IMRT
Study NCT02427841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02427841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT02427841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT00747227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified light transmission intraocular lens
Description: violet visible light blocking acrylic intraocular lens
Study NCT03151382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandospirone Citrate
Description: Tandospirone, 30-60 mg/d
Study NCT03151382 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Donepezil Hydrochloride
Description: Donepezil, 10 mg/d
Study NCT00747227 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: monofocal acrylic intraocular lens
Description: conventional hydrophobic acrylic intraocular lens
Study NCT02895204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Maillard reacted whey protein (F-MRP)
Description: 6g of powder containing 4.2g fermented maillard reacted whey protein
Study NCT03151382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: Donepezil, 10 mg/d
Study NCT03366857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen 30 %
Description: The oxygen concentration will be set at 30%.
Study NCT03366857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen 80 %
Description: The oxygen concentration will be set at 80%.
Study NCT04238936 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum amyloid A values
Description: Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
Study NCT04238936 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)
Description: Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
Study NCT01484080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF + Paclitaxel
Description: Priming Period:~Oral BIBF 1120 will be administered during 2 weeks at the dose determined during the phase-I part that can be combined safely with weekly paclitaxel, on a continuous schedule for 14 days.~One week washout is planned before starting the treatment phase.~Treatment Phase:~Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 + BIBF 1120 recommended dose bid po days 1-21 q 21 days. (BIBF 1120 morning dose is skipped on the paclitaxel administration days).
Study NCT01484080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 q 21 days. A total of 4 cycles will be administered in both arms.
Study NCT01735318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril Tablets 40 mg
Description: 40 mg tablet once a day
Study NCT01735318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: 40 mg tablet once a day
Study NCT01359930 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study NCT01359930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone and Bupropion SR
Description: 25mg bid/day (NX) 200mg bid/day (BUP)